KR101216410B1 - Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract and resverol extract - Google Patents
Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract and resverol extract Download PDFInfo
- Publication number
- KR101216410B1 KR101216410B1 KR1020110144316A KR20110144316A KR101216410B1 KR 101216410 B1 KR101216410 B1 KR 101216410B1 KR 1020110144316 A KR1020110144316 A KR 1020110144316A KR 20110144316 A KR20110144316 A KR 20110144316A KR 101216410 B1 KR101216410 B1 KR 101216410B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- sunscreen
- skin
- titanium dioxide
- effect
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000002537 cosmetic Substances 0.000 title claims abstract description 15
- 230000000694 effects Effects 0.000 title abstract description 24
- 238000012216 screening Methods 0.000 title 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 230000000475 sunscreen effect Effects 0.000 claims abstract description 35
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 34
- 239000000516 sunscreening agent Substances 0.000 claims abstract description 33
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 22
- 239000004575 stone Substances 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 8
- 230000001914 calming effect Effects 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 2
- 241001377695 Polygonum arenastrum Species 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 14
- 206010034972 Photosensitivity reaction Diseases 0.000 description 9
- 208000007578 phototoxic dermatitis Diseases 0.000 description 9
- 231100000018 phototoxicity Toxicity 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000218671 Ephedra Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 231100000760 phototoxic Toxicity 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000011882 ultra-fine particle Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- -1 sophoriside Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ZQPVHVKWCGZNDW-NVYKSAHZSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZQPVHVKWCGZNDW-NVYKSAHZSA-N 0.000 description 1
- NRTKYSGFUISGRQ-UHFFFAOYSA-N (3-heptanoyloxy-2,2-dimethylpropyl) heptanoate Chemical compound CCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCC NRTKYSGFUISGRQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 240000008482 Asclepias tuberosa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- NBGJGWFIDMDCAW-UHFFFAOYSA-N egonol-beta-gentiobioside Natural products C=1C=2C=C(C=3C=C4OCOC4=CC=3)OC=2C(OC)=CC=1CCCOC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O NBGJGWFIDMDCAW-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 돌외잎추출물과 호장근추출물을 함께 함유하여 지속적인 피부진정효과를 나타내는 자외선차단제 조성물에 관한 것으로, 물리적 자외선 차단제인 초미립자 이산화티탄 함유로 인한 활성산소 생성을 억제하기 위해 항산화력이 탁월한 제주산 돌외잎추출물과 전자공여능이 우수한 호장근추출물을 함께 함유하여 광독성 문제를 해결하여 지속적인 피부 진정효과를 나타내는 자외선 차단 기능성 화장료 조성물에 관한 것이다.The present invention relates to a sunscreen composition which contains a stone extract and a long root extract with a continuous skin soothing effect, and has an excellent antioxidant power in order to suppress the generation of active oxygen due to the ultrafine titanium dioxide containing physical sunscreen The present invention relates to a sunscreen functional cosmetic composition that contains a stone extra leaf extract and e.
Description
본 발명은 자외선 차단 기능성 화장료 조성물에 관한 것으로서, 상세하게는 물리적 자외선 차단제인 초미립자 이산화티탄 함유로 인한 활성산소 생성을 억제하기 위해 항산화력이 탁월한 돌외잎추출물을 함유하고, 동시에 호장근추출물을 함유하여 전자공여능을 부여함으로서 지속적인 항산화력을 나타내어 광독성 문제를 해결하여 피부 진정효과를 나타내는 돌외잎추출물과 호장근추출물을 함유한 피부 진정 자외선 차단 기능성 화장료 조성물에 관한 것이다The present invention relates to a sunscreen functional cosmetic composition, and in particular, to inhibit the generation of free radicals due to the ultrafine titanium dioxide containing physical sunscreen, containing an excellent stone extract extract excellent in antioxidant power, at the same time containing The present invention relates to a skin calming sunscreen functional cosmetic composition containing a monocotyledonous extract and a long root muscle extract which exhibit a sedating effect by solving the phototoxicity problem by providing a continuous antioxidant power by imparting an electron donating ability.
자외선은 피부에 비타민 D를 형성하여 뼈의 성장을 촉진시켜 구루병을 억제하고, 표피세포의 분화를 촉진하여 피부장벽을 튼튼하게 해 주는 긍정적인 면이 존재한다. 하지만, 자외선은 피부흑화, 홍반, 콜라겐 파괴로 인한 주름발생, 심지어는 피부암을 일으키는 성분으로 알려져 있다.
Ultraviolet rays form vitamin D in the skin to promote bone growth, inhibit rickets, and promote the differentiation of epidermal cells to strengthen the skin barrier. However, ultraviolet rays are known to cause skin blackening, erythema, wrinkles caused by collagen destruction, and even skin cancer.
자외선을 억제하기 위한 자외선 차단제가 기능성 화장품으로 분류되어 많은 연구가 진행되어 오고 있다. 자외선 차단제는 물리적 차단제와 화학적 차단제로 분류할 수 있다. 물리적 차단제는 자외선을 산란시켜 피부로 자외선 침투를 막는 것이고, 화학적 차단제는 자외선을 흡수시켜 피부로의 자외선 침투를 억제하는 것이다.A lot of researches have been conducted since sunscreens for inhibiting UV rays are classified as functional cosmetics. Sunscreens can be classified into physical and chemical blockers. Physical blocking agents scatter ultraviolet rays to prevent ultraviolet penetration into the skin, and chemical blocking agents absorb ultraviolet rays to inhibit ultraviolet penetration into the skin.
물리적 차단제는 차단작용이 우수하고 접촉성 피부염과 같은 부작용은 없으나 불투명하기 때문에 크림이나 로션에 많이 배합되면 미관상 좋지 않은 단점이 있다. 반면에 화학적 차단제인 자외선 흡수제는 피부에 바른 후 투명하기 때문에 미관상 좋으나 많이 배합되면 접촉성 피부염을 일으킬 수 있으므로 주의하여야 한다. 최근 유럽을 중심으로 자외선 흡수제인 화학적 차단제의 접촉성 피부염 발생에 대한 문제로 인해 물리적 차단제를 주로 사용하도록 법적으로 규제하려고 하고 있다.
Physical blockers are excellent in blocking action and do not have side effects such as contact dermatitis, but because they are opaque, when combined with a lot of creams or lotions, there is an aesthetic disadvantage. On the other hand, UV absorbers, which are chemical blockers, are aesthetically pleasing because they are transparent after being applied to the skin. Recently, due to the problem of contact dermatitis caused by a chemical absorber, a UV absorber, mainly in Europe, it is trying to legally regulate the use of physical blockers.
물리적 차단제는 자외선과 가시광선을 반사 또는 분산시키는 불투명한 물질로서 이산화티탄(titanium dioxide, TiO2), 산화아연(zinc oxide, ZnO) 등이 사용되고 있다. 이산화티탄의 굴절률은 2.72이고 산화아연의 굴절률은 2.02로 이산화티탄의 효과가 좋아 더 선호되고 있어 주성분으로 많이 사용된다. 이산화티탄은 자외선 차단효과가 우수하고 접촉성 피부염의 부작용이 작지만, 불투명한 물질로 백탁현상이 일어나 미용상으로 좋지 않다. 최근 백탁현상을 줄이기 위해 이산화티탄의 입자크기를 줄이려는 연구가 진행되고 있다. 입자크기를 줄인 초미립자 이산화티탄은 백탁현상이 줄어들고 사용감도 좋아져서 많이 연구되고 있다. 그런데 초미립자 이산화티탄의 경우 입자크기를 390 nm이하로 줄이게 되면 다음과 같은 기작으로 활성산소인 수포옥사이드라디칼(superoxide radical), 싱글렛옥시젠(siglet oxygen), 히드록시 라디칼(hydroxy radical), 히드로페록시라디칼(hydroperoxy radical)를 일으키게 된다.Physical barriers are opaque materials that reflect or disperse ultraviolet rays and visible light, and titanium dioxide (TiO 2 ) and zinc oxide (ZnO) are used. Titanium dioxide has a refractive index of 2.72 and zinc oxide has a refractive index of 2.02, which is favored by titanium dioxide. Titanium dioxide has excellent UV-blocking effect and small side effects of contact dermatitis, but it is not good for cosmetic because of opacity of white matter. Recently, research to reduce the particle size of titanium dioxide in order to reduce the clouding phenomenon is in progress. Ultrafine titanium dioxide with reduced particle size has been studied a lot because of less whitening and better usability. However, in the case of ultrafine titanium dioxide, when the particle size is reduced to 390 nm or less, the following mechanisms are used: active oxides such as superoxide radical, singlet oxygen, hydroxy radical, and hydroperoxy It generates a radical (hydroperoxy radical).
그 자체는 독성이 없다고 하더라고 자외선을 흡수하여 화학적으로 활성화되어 활성산소를 발생하여 독성이 생기는데, 이와 같은 물질을 광독성 물질이라 부른다.Although it is not toxic itself, it absorbs ultraviolet rays and is chemically activated to generate free radicals, which are toxic. Such substances are called phototoxic substances.
문제는 자외선 차단제에 가장 많이 사용되는 이산화티탄이 백탁현상을 해결하기 위하여 초미립자로 가공을 하게 되면, 그 자체의 독성은 없으나 피부에 도포시 자외선에 의해 활성산소를 발생시켜서 독성을 일으키는 광독성물질이 된다는 점이다.The problem is that when titanium dioxide, the most commonly used sunscreen, is processed into ultra-fine particles to solve the clouding phenomenon, it does not have its own toxicity, but when applied to the skin, it becomes a phototoxic substance that generates free radicals by ultraviolet rays. Is the point.
본 발명은 상기된 문제점을 해결하기 위하여 발명된 것으로서, 본 발명은 초미립자 이산화티탄으로 인한 활성산소 발생 및 광독성 문제를 해결하기 위하여 돌외잎추출물과 호장근추출물을 함께 함유하여 상승효과를 나타내며, 이들의 지속적인 항산화효과로 피부 진정효과와 자외선 차단효과, 그리고 백탁현상의 문제를 해결할 수 있는 피부 진정 자외선 차단 기능성 화장료 조성물을 제공함을 그 목적으로 한다.
The present invention has been invented in order to solve the above problems, the present invention has a synergistic effect by containing together the stone extracts and ephedra root extracts in order to solve the problem of active oxygen generation and phototoxicity caused by ultra-fine titanium dioxide, The purpose of the present invention is to provide a soothing sunscreen functional cosmetic composition that can solve the skin soothing effect, sunscreen effect, and the problem of clouding with continuous antioxidant effect.
본 발명에 의한 돌외잎추출물과 호장근추출물을 함유한 피부 진정 자외선 차단 기능성 화장료 조성물은 입자크기가 370 nm이하의 초미립자 이산화티탄을 포함하는 자외선 차단 기능성 화장료에 사용되는 것으로서,The skin soothing sunscreen functional cosmetic composition containing the extra stone leaf extract and the root extract of the present invention is used in a sunscreen functional cosmetic containing ultrafine titanium dioxide having a particle size of 370 nm or less,
에탄올을 이용하여 돌외의 잎에서 추출한 돌외잎추출물을 0.1 내지 30.0 중량 %와 에탄올을 이용하여 호장근에서 추출한 호장근추출물을 0.1 내지 30.0 중량 %를 포함하고 있는 것을 특징으로 한다. It is characterized in that it comprises 0.1 to 30.0% by weight of the stone extract extracted from the leaves of the stone other than ethanol, and 0.1 to 30.0% by weight of the extract of the root of the root of the extract using ethanol.
본 발명에 의한 피부 진정 자외선 차단 기능성 화장료 조성물은 초미립자 이산화티탄 사용으로 인한 활성산소 발생과 광독성 문제를 다량의 사포닌 성분을 함유한 돌외잎추출물과 호장근추출물을 복합 함유하여 지속적인 항산화효과로 피부 진정효과와 자외선 차단효과, 그리고 백탁현상을 해결할 수 있다.
The skin calming sunscreen functional cosmetic composition according to the present invention has a sedative effect on skin with a continuous antioxidant effect by containing a complex of foliar leaf extract and P. aeruginosa extract containing a large amount of saponin components due to the generation of active oxygen and phototoxicity caused by the use of ultrafine titanium dioxide And sunscreen effect, and cloudiness can be solved.
본 발명에 의한 피부 진정 자외선 차단 기능성 화장료 조성물은 돌외잎추출물과 호장근추출물을 포함하고 있는 것을 특징으로 한다.The skin calming sunscreen functional cosmetic composition according to the present invention is characterized in that it comprises a stone extract extract and splenic root extract.
돌외는 박과에 속하는 다년생 덩굴초본으로서 우리나라 남부와 중국남부, 일본 등에 분포하며 우리나라에서는 남부지역과 제주도 등의 섬에서 자생한다. 잎이 어긋나고 5개의 작은 잎이 가진 겹잎이며 새발모발을 하고 있다. 꽃은 8-9월에 황록색으로 핀다. 과실은 장과로 지름 6-8 cm이고, 교고담이라고도 부른다. 본 발명에서는 돌외의 잎에서 추출한 추출물을 사용하는데, 본 발명에서 사용되는 돌외잎추출물의 주요 성분으로는 다마란 (dammarane)계 사포닌인 지페오사이드(gypenoside)와 그 밖에 프리메베로사이드(promeveroside), 소포로사이드(sophoriside), 비스데스모사이드(bisdesmoside), 젠티오바이오사이드(gentiobioside), 루티노사이드(rutionoside) 등의 배당체와 스테로이드, 당류 및 색소를 함유하고 있다. 돌외 잎에서 분리된 다마란계 사포닌은 인삼의 사포닌과 동일한 것이 많고, 동계열의 배당체로서 6종의 새로운 지페노사이드가 알려져 있고, 이들은 지페노사이드 LXXX, LXXXI, LXXXⅡ, LXXXⅢ, LXXXIV, LXXXV 로서 그 구조도 밝혀져 있다. 또한 지페노사이드는 비만, 고혈압, 항염, 항당뇨, 면역기능, 콜레스테롤 강화작용, 심혈관계 질환예방, 진해, 거담, 강장작용 등이 있다.
Dol-eo is a perennial vine herb belonging to the family of fruits, distributed in southern Korea, southern China, Japan, etc., and native to southern islands and Jeju islands. The leaves are alternate, and the leaf is made up of five small leaves. Flowers bloom yellow-green in August-September. Fruit is berry, 6-8 cm in diameter, also called Kyogodam. In the present invention, an extract extracted from the leaves of the dodol is used, and the main components of the dodol leaf extract used in the present invention include dammarane-based saponins, gypenoside and other primerosides (promeveroside), It contains glycosides, such as sophoriside, bisdesmoside, gentiobioside and rutionoside, and steroids, sugars and pigments. Damaran-based saponins isolated from dodol leaves are the same as the saponins of ginseng, and six new zipenosides are known as glycosides of the same family. Its structure is also revealed. Zipenoside also has obesity, hypertension, anti-inflammatory, anti-diabetic, immune function, cholesterol-enhancing action, cardiovascular disease prevention, Jinhae, expectoration, tonic action.
호장근은 다년초인 호장, 왕호장 및 둥근잎호장 등 마디풀과에 속하는 호장의 뿌리 및 근경을 말린 것으로, 호장근은 옛날부터 민간에서 이뇨, 통경제, 진정제로 사용되어 왔으며, 완하, 이뇨, 통경, 화농성 피부염, 뇨도염, 방광염, 고혈압, 암 동맥경화 등의 여러 질병을 치료하기 위하여 우리나라를 비롯하여 동양권의 전통의학에서 이용되어 왔다. 그러나 호장근추출물에 대한 자외선차단제에 의한 피부진정효과에 대해서는 어떤 개시나 교시된 바가 없다.
Hojang-geun is dried dried roots and rhizomes of the Mardipulaceae including perennial herbaceous ginseng, king-ho and round-leafed soybean paste. Hojang-geun has been used as a diuretic, diuretic, and sedative in the private sector since ancient times. It has been used in traditional medicine in Asian and other countries to treat various diseases such as purulent dermatitis, urinary tract infection, cystitis, hypertension and cancer arteriosclerosis. However, no disclosure or teaching has been made of the skin soothing effect of sunscreen on extracts.
이에, 본 발명자들은 초미립자 이산화티탄으로 인한 활성산소를 없애기 위해 피부에 부작용없이 안전하게 사용할 수 있는 자외선 차단제에 대한 연구하던 중 돌외잎추출물의 항산화효과가 피부 진정효과를 나타내는 것을 확인하였으나, 계속적으로 항산화효과를 나타낼 수 없는 점을 확인하였으며, 이에 호장근추출물의 전자공여능 효능으로 인해 돌외잎추출물이 지속적인 항산화효과를 나타낼 수 있게 하는 네트워크 항산화시스템으로 상승효과를 나타내는 광독성을 일으키지 않는 피부 진정효과를 우수하게 나타내는 것을 확인하고, 본 발명을 완성하였다.
Thus, the present inventors have been found that the antioxidant effect of the foliar leaf extract shows a calming effect of the skin while researching on a sunscreen that can be safely used without side effects on the skin to eliminate the active oxygen caused by ultra-fine titanium dioxide It was confirmed that it could not be expressed, and due to the electron donating effect of the root extract, it is a network antioxidant system that allows the extracellular leaf extract to have a continuous antioxidant effect, which shows excellent skin soothing effect that does not cause synergistic phototoxicity. It was confirmed that the present invention was completed.
즉, 본 발명에서는 초미립자 이산화티탄 사용으로 인한 활성산소 발생과 광독성 문제를 다량의 사포닌 성분을 함유한 돌외잎추출물과 호장근추출물을 복합 함유하여 지속적인 항산화효과로 피부 진정효과와 자외선 차단효과, 그리고 백탁현상을 해결할 수 있었다. 돌외잎추출물에 함유된 사포닌 성분 중에는 지페노사이드를 다량 함유하고 있는데, 이 지페노사이드가 주요한 항산화효과를 나타내는 효능성분이다. 또한 호장근추출물은 레스베라트롤(resveratrol)을 함유하여 항염증효과와 전자공여능 효과를 나타낼 수 있다. 특히, 제주산의 경우에는 이러한 성분들이 다량 포함되어 있어서 더욱 효과적이다.
That is, in the present invention, the active oxygen generation and phototoxicity problems caused by the use of ultra-fine titanium dioxide are combined with a stony leaf extract and a long root extract containing a large amount of saponin. The problem could be solved. Among the saponin components contained in the monocotyledonous extract, it contains a large amount of phenenoside, which is a potent ingredient showing a major antioxidant effect. In addition, the extract of E. coli may have anti-inflammatory effect and electron donating effect by containing resveratrol. In particular, in the case of Jeju acid it is more effective because it contains a large amount of these components.
이를 좀더 상세히 살펴본다.Let's look at this in more detail.
초미립자 이산화티산에 의해 생성된 활성산소는 프리라디칼을 가지고 있다. 라디칼은 다른 분자로부터 전자를 빼앗아 세포의 지질과 단백질, 핵산과 같은 중요한 물질을 산화시켜 손상시킨다. 항산화제란 기본적으로 전자기증에 능통한 화합물이다. 신속하게 자신의 전자 중에 하나를 포기하여 프리라디칼을 해체할 수 있게 한다. 이 과정에서 항산화제 그 자체는 무력한 프리라디칼이 되어 인체에 상해를 입히지 않는다. 여기서 만일 다른 항산화제가 존재하면 전자 하나를 기증하여 항산화파워를 상실한 항산화제는 원래의 항산화제 위치로 환원된다.
Free radicals produced by ultra-fine particulate dioxide have free radicals. Radicals take electrons from other molecules and oxidize and damage important substances such as lipids, proteins and nucleic acids in cells. Antioxidants are basically compounds that are good at electromagneticosis. Quickly abandon one of his former electrons so he can break free radicals. In the process, the antioxidant itself becomes a helpless free radical, which does not harm the human body. Here, if another antioxidant is present, the antioxidant that loses the antioxidant power by donating one electron is reduced to the original antioxidant site.
일반적으로 전자기능이 좋으면 항산화능력이 좋지만, 반드시 그렇치는 않다. 돌외잎추출물은 상대적으로 항산화능력이 좋고, 호장근추출물은 전자공여능이 좋은 것이다. 즉, 항산화력이 좋은 돌외잎추출물은 전자를 기증하여 프리라디칼을 해체하여 활성산소를 억제하고, 돌외잎추출물은 인체에 무해한 프리라디칼로 변해 더 이상 항산화제의 기능을 상실한다. 그런데 여기에 항산화력보다는 전자기증능력이 우수한 호장근추출물이 같이 존재하면 호장근추출물에서 전자하나를 기증하여 상실된 돌외잎추출물이 원래의 항산화제 위치로 환원되는 것이다.
In general, good electronic function is good antioxidant capacity, but not necessarily. Outer leaves extract has a relatively good antioxidant capacity, and the root extracts have good electron donating ability. That is, the extracellular leaf extract with good antioxidant power decomposes free radicals by donating electrons to inhibit free radicals, and the extracellular leaf extract turns into free radicals, which are harmless to the human body, and no longer function as antioxidants. By the way, if the presence of eukaryotic muscle extract with excellent electromagnetism ability than the antioxidant power is present, the extra-leaf extract extracted by donating one electron from the eukaryotic muscle extract is reduced to the original antioxidant site.
한편, 본 발명에 의한 피부 진정 자외선 차단 기능성 화장료 조성물에는 돌외잎추출물을 0.1 내지 30.0 중량 %를 포함하고, 호장근추출물을 0.1 내지 30.0 중량 %를 포함한다. 여기서 돌외잎추출물이 0.1 중량 %이하인 경우에는 항산화효과가 나타나지 않고, 30.0 중량 %이상의 경우에는 자외선차단제의 제형의 안정성(Stability)이 유지되지 않기 때문이며, 호장근추출물이 0.1 중량 %이하인 경우에는 전자공여능 효과가 나타나지 않고, 30.0 중량 %이상의 경우에는 자외선차단제의 제형의 안정성(Stability)이 유지되지 않기 때문이다.On the other hand, the skin soothing sunscreen functional cosmetic composition according to the present invention comprises 0.1 to 30.0% by weight of the extra-foliar extract, and 0.1 to 30.0% by weight of the root extract. Here, if the stone extract is less than 0.1% by weight, the antioxidant effect does not appear, and if it is more than 30.0% by weight, the stability of the formulation of the sunscreen is not maintained, and when the extract is less than 0.1% by weight, electron donating ability This is because the effect does not appear, and the stability of the formulation of the sunscreen is not maintained at 30.0% by weight or more.
본 발명의 조성물에서 유효성분인 제주산 돌외잎추출물과 호장근추출물의 제조는 다음과 같다. 먼저, 돌외잎과 호장근를 정제수로 세척하고 음지에서 자연 건조시킨 후 분쇄기를 이용하여 분쇄한다. 분쇄된 돌외잎과 호장근을 각각 에탄올에 넣고 추출한 후 3회 반복하여 여과한다. 열수추출법나 유기용매 추출법보다 에탄올 추출법을 선택한 이유는 열수추출법에서는 물에 용해되는 유효성분이 작고, 끊는 물에 의해 유효성분이 파괴될 수 있는 위험성이 있고, 유기용매는 추출효율은 좋지만 잔존 유기용매로 인한 부작용이 우려되기 때문이다. 여과물을 감압 농축하여 돌외 에탄올추출물과 호장근 에탄올 추출물을 얻는다.
Preparation of Jeju-dodol leaf extract and jangjanggeun extract as an active ingredient in the composition of the present invention is as follows. First, the stone leaves and knotweed are washed with purified water, naturally dried in the shade, and then ground using a grinder. The crushed stone leaves and ephedra root were put in ethanol, and extracted and filtered three times. The reason why the ethanol extraction method was chosen over the hot water extraction method or the organic solvent extraction method is that in the hot water extraction method, the active ingredient dissolved in water is small and there is a risk that the active ingredient may be destroyed by the cutting water. This is because side effects are concerned. The filtrate was concentrated under reduced pressure to obtain an extra-dolan ethanol extract and kojangeun ethanol extract.
본 발명에서 사용되는 돌외잎추출물은 멜라닌 생성과 티로시나아제 활성을 억제하여 하는 등 미백효과가 알려져 있고, 본 발명에서는 초미립자 이산화티탄의 자외선 노출로 인한 활성산소를 억제하기 위한 항산화효과를 측정하고, 지속적인 항산화효과를 나타내기 위해 전자공여능이 있는 호장근추출물을 함께 함유하여 초미립자 이산화티탄으로 인한 지속적인 광독성 억제효능을 확인하여 본 발명을 완성하였다.Whitening leaf extract used in the present invention is known to whiten effect, such as inhibiting melanin production and tyrosinase activity, in the present invention to measure the antioxidant effect for inhibiting the active oxygen caused by ultraviolet exposure of ultrafine titanium dioxide, The present invention was completed by confirming the continuous phototoxic inhibitory effect due to ultrafine titanium dioxide by containing elongated root extract with electron donating ability to show a continuous antioxidant effect.
본 발명의 자외선 차단제의 기능성 화장료 조성물은 통상적으로 제조되는 로션, 크림 제형으로 제조될 수 있다. 이하 본 발명의 이해를 돕기 위하여 바람직한 실시한 예를 제시한다. 그러나 하기의 실시한 예는 본 발명을 더욱 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시한 예에 의해 본 발명의 내용이 한정되는 것은 아니다.
The functional cosmetic composition of the sunscreen of the present invention may be prepared in a lotion, cream formulation that is conventionally prepared. Hereinafter, preferred examples are provided to help understanding of the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.
하기의 실시예에서는 돌외잎추출물과 호장근추출물의 항산화효과인 수퍼옥사이드 디스뮤타아제 (superoxide dismutase) 유사 활성을 측정하여 항산화효과를 확인하였다. 또한 돌외잎추출물과 호장근추출물을 대상으로 전자공여능(electron donating ability)을 측정하여 지속적인 항산화효과를 나타낼 수 있는 여부를 판단한다. 초미립자 이산화티탄을 함유한 자외선차단제 제형에서 제주산 돌외잎추출물과 호장근추출물을 복합함유하는 할 때 광독성의 저해효과를 측정을 통해 본 발명의 피부 진정효과를 확인하고자 하였다.
In the following examples, the antioxidant effect was confirmed by measuring the superoxide dismutase-like activity, which is the antioxidant effect of the extra-leaf extract and the extract of Escherichia coli. In addition, by measuring the electron donating ability of the extra stone leaf extract and the extract of ephedra root to determine whether it can show a continuous antioxidant effect. Ultrafine particles In the sunscreen formulation containing titanium dioxide, Jeju edible leaf extract and Escherichia coli extract were combined to determine the skin soothing effect of the present invention by measuring the inhibitory effect of phototoxicity.
실시 제조예 1 : 에탄올 돌외잎추출물의 제조Example 1 Preparation of Ethanol Extracellular Leaf Extract
돌외잎을 정제수로 세척하고 음지에서 자연 건조한 후 분쇄기를 이용하여 2~3 cm의 크기로 분쇄한다. 분쇄된 돌외잎 1kg을 에탄올 9L에 넣고 15 내지 25 ℃에서 24시간 동안 추출하였다. 상기 추출물을 와트만 3번 여과지로 여과하고 나서, 냉각 콘덴서가 달리 추출장치를 이용하여 30 내지 40 ℃에서 감압 농축하여 에탄올 돌외잎추출물을 40.7 g을 얻었다.
The stone leaves are washed with purified water, dried naturally in the shade, and then ground to a size of 2 to 3 cm using a grinder. 1 kg of crushed stone leaves were put in 9 L of ethanol and extracted for 24 hours at 15 to 25 ℃. The extract was filtered using Whatman No. 3 filter paper, and the cooling condenser was concentrated under reduced pressure at 30 to 40 ° C. using an extractor to obtain 40.7 g of ethanol monocotyledonous extract.
실시 제조예 2 : 에탄올 호장근추출물의 제조Example 2 Preparation of Ethanol Extracts
상기 실시 제조예 1에서 돌외잎 대신에 호장근을 사용한 것을 제외하고는 동일하고, 에탄올 호장근추출물을 38.7 g을 얻었다.
Except for using ephedra root instead of stone leaves in Preparation Example 1, 38.7 g of ethanol ephedra extract was obtained.
실험 1 : 항산화효과 측정Experiment 1: Antioxidant Effect Measurement
항산화효과의 대표적인 측정방법인 수포옥사이드 디스뮤타아제 (superoxidase dismutase, SOD) 유사활성을 측정하였다. SOD 유사활성은 측정방법은 다음과 같다. 시료용액인 각각 돌외잎추출물과 호장근추출물 0.2 ml에 Tris-HCl 완충용액(pH 8.5) 3 ml와 7.2 mM 파이로겔롤 (pyrogallol) 0.2 ml 을 가하고 10초간 와류혼합 (vortex mix) 후 25 ℃에서 10분간 반응시킨 후 1 M HCl 1 ml를 가하여 반응을 정지시키고 420 nm에서 흡광도로 산화된 파이로겔롤 양을 측정하였다. SOD 유사활성은 시료 첨가군과 무 첨가군의 흡광도에서 산화된 파이로겔롤 차이로 나타내었다.Superoxidease dismutase (SOD) -like activity, a representative measure of antioxidant effect, was measured. SOD-like activity is measured as follows. 3 ml of Tris-HCl buffer solution (pH 8.5) and 0.2 ml of 7.2 mM pyrogallol were added to 0.2 ml of the extrafoliar extract and the root extract of the root extract, respectively, and then vortex mixed for 10 seconds at 25 ° C. After reacting for 10 minutes, 1 ml of 1 M HCl was added to stop the reaction, and the amount of pyrogelol oxidized by absorbance at 420 nm was measured. SOD-like activity was expressed by the difference of oxidized pyrogelol in absorbance of the sample addition group and no addition group.
SOD 유사활성도(%) = {1-(시료첨가군 흡광도/무첨가군 흡광도)} ×100 SOD-like activity (%) = {1- (sample absorbance / non-addition absorbance)} × 100
돌외잎추출물과 호장근추출물의 SOD 유사활성을 측정한 결과는 각각 85.7%, 13.5%이며, 돌외잎추출물은 호장근추출물에 비하여 강한 항산화효과를 나타냄을 알 수 있다.
The SOD-like activity of the extra-leaf leaves and P. root extracts was 85.7% and 13.5%, respectively, and the extra-leaf leaves showed stronger antioxidant effects than the extracts of the roots.
실험 2 : 전자공여능 측정Experiment 2: Measurement of Electron Donating Ability
전자공여능은 다음과 같은 방법으로 측정할 수 있다. 시료용액 2 ml에 0.2 mM의 1,1-diphenyl-2-picrylhydrazyl(DPPH) 1 ml을 넣고 10초간 와류혼합(vortex mix)한 후 25에서 30분간 반응시킨 후 517 nm에서 흡광도를 측정하였다. 전자공여능은 시료첨가군과 무첨가군의 흡광도 차이를 백분율로 나타내었다. Electron donating ability can be measured by the following method. 1 ml of 0.2 mM 1,1-diphenyl-2-picrylhydrazyl (DPPH) was added to 2 ml of the sample solution, followed by vortex mix for 10 seconds, and reacted for 25 to 30 minutes. The absorbance was measured at 517 nm. The electron donating ability was expressed as a percentage difference in absorbance between the sample addition group and the no addition group.
전자공여능 (%) = {1-(시료첨가군 흡광도/무첨가군 흡광도)} ×100 Electron donating ability (%) = {1- (sample absorbance / non-addition absorbance)} × 100
돌외잎추출물과 호장근추출물의 전자공여능은 각각 25.7%, 84.4%를 나타내었다. 호장근추출물의 전자공여능이 돌외잎추출물에 비하여 강한 전자공여능을 나타냄을 알 수 있다.
The electron donating abilities of the extra-leaf leaves extract and the root extract were 25.7% and 84.4%, respectively. It can be seen that the electron donating ability of the E. coli extract exhibits a strong electron donating ability compared to the extra-leaf extract.
이로써 돌외잎추출물과 호장근추출물을 함께 함유할 때 항산화능력을 돌외잎추출물이 강하고, 여기에 호장근추출물이 돌외잎추출물에 전자공여능을 제공하여 돌외잎추출물의 지속적인 항산화능력을 제공할 수 있는 네트워크 항산화제 시스템을 구축되었음을 알 수 있다.
This results in a strong anti-stone leaf extract with antioxidant capacity when the extra-leaf leaf extract and the root extract are combined together, and the root extract extract provides electron donating ability to the extra-leaf leaf extract to provide continuous antioxidant capacity of the extra-leaf leaf extract. It can be seen that the antioxidant system was established.
실시 제조예 3: 피부외용 자외선 차단제의 제조Example Preparation 3 Preparation of External Skin Sunscreen
본 발명에 따른 초미립자 이산화티탄의 활성산소 방출로 인한 광독성, 즉 피부안전성과 돌외잎추출물과 호장근추출물을 함유한 자외선차단제의 피부 진정효과를 확인하기 위한 실험이다. 자외선 차단제의 기본 제형을 자외선 차단지수(Sun Protection Factor, SPF) 50을 기준으로 다음과 같은 성분으로 제조하였다. 자외선 차단크림 제조를 위하여 한쪽 수성 비이커에는 정제수, 글리세린 등 수용성성분, 고분자 및 불투명 물리적차단제인 이산화티탄을 함유하여 혼합하여 75 ℃로 가온한다. 다른 유성 비이커에는 사이클로헥사실록산 등의 유용성 성분과 화학적 자외선차단제, 그리고 계면활성제를 함유하여 혼합하며 75 ℃까지 가온한다. 수성 비이커와 유성 비이커를 혼합하여 3600 rpm의 속도로 4분동안 호모믹서로 혼합한다. 그 이후에 패덜믹서로 혼합하면서 냉각하며 50 ℃이하에서 추출물과 향료, 방부제를 혼합하여 자외선 차단제를 완성한다. 다만, 이산화티탄, 돌외잎추출물, 호장근추출물의 함량만 아래의 표와 같이 달리하여 제조하였다. It is an experiment for confirming the skin toxicity of the ultrafine titanium dioxide according to the present invention due to the release of free radicals, that is, the skin safety and the soothing effect of the sunscreen containing crustacean extract and ephedra extract. The basic formulation of the sunscreen was prepared with the following ingredients based on the Sun Protection Factor (SPF) 50. To prepare the sunscreen cream, one aqueous beaker contains water-soluble components such as purified water and glycerin, a polymer, and titanium dioxide, an opaque physical barrier agent, and the mixture is heated to 75 ° C. Other oily beakers are mixed with oil-soluble components such as cyclohexasiloxane, chemical sunscreen and surfactant, and warmed to 75 ° C. The aqueous beaker and the oil beaker are mixed and mixed with a homomixer for 4 minutes at a speed of 3600 rpm. After that, the mixture is cooled by mixing with a paddle mixer and the extract, the fragrance, and the preservative are mixed below 50 ° C. to complete the sunscreen. However, only the content of titanium dioxide, stone extra-leaf extract, ephedra root extract was prepared as shown in the table below.
ingredient
실험 3: 광독성에 의한 피부누적 자극시험Experiment 3: cumulative skin irritation test by phototoxicity
상기 실시 제조예 3에서 제조한 각 자외선차단제를 사용하여, 20~40대의 건강한 성인 남녀 30명 (남자-15명, 여자-15명)을 대상으로 윗 팔뚝 부위에 격일로 총 9회의 24시간 누적첩포를 시행하고 각각 자외선-A, 자외선-B를 각각 3분간 주사하여,자외선 노출과 활성산소, 광독성의 영향을 측정하였다. 첩포방법은 핀 챔버(Finn Chamber, Epitest, Ltd, 핀란드)를 이용하였다. 챔버에 상기 실시 제조예 3에서 제조한 각 자외선차단제를 15 ㎕씩 적하한 후 자외선-A, 자외선-B를 차례로 각각 3분씩 주사한 후에 첩포를 실시하였다. 매회 피부에 나타난 반응 정도를 하기 수학식을 이용하여 점수화하였다. Using each of the sunscreens prepared in Preparation Example 3, a total of nine 24 hours accumulates every other day on the upper forearm of 30 healthy males and females (man-15 and woman-15) in their 20s and 40s. Patches were performed and UV-A and UV-B were injected for 3 minutes, respectively, and the effects of UV exposure, free radicals, and phototoxicity were measured. The patching method used a fin chamber (Finn Chamber, Epitest, Ltd, Finland). 15 µl of each of the sunscreens prepared in Preparation Example 3 was added dropwise to the chamber, and then UV-A and UV-B were sequentially injected for 3 minutes, followed by patching. The degree of response that appeared on the skin each time was scored using the following equation.
평균반응도 = {[반응지수×반응도) / (총피검자수×최고점수)] × 100} / 검사횟수Average responsiveness = {[response index × responsiveness) / (total number of subjects × highest score)] × 100} / number of tests
이때, 반응도에서 ±는 1점, +는 2점, ++는 4점의 점수를 부여하며, 평균반응도가 3미만일 때 안전한 조성물로 판정하였다. 결과는 아래표에 나타내었다.At this time, ± 1 point in the reaction, + 2 points, + + gives a score of 4 points, was determined as a safe composition when the average reactivity is less than 3. The results are shown in the table below.
여기서 반응도는 홍반의 반응도이다. 즉, 피부가 자극을 받으면 빨간색으로 변하는 것을 홍반이라고 하는데, 빨간색이 진할수혹 홍반 반응도가 심해지는데, 빨간 정도를 기준으로 반응도를 측정하였다.
Where reactivity is the reactivity of erythema. That is, when the skin is irritated, the red color is called erythema, and the red color is deeply red, and the erythema responsiveness is increased.
위의 표에 나타난 바와 같이, 비교예4인 일반입자크기 이산화티탄의 경우는 0.37로 매우 안전한 조성물을 나타내지만, 비교예1의 초미립자 이산화티탄이 포함된 경우 평균반응도가 2.30으로 안전한 조성물이지만 다소 높은 피부반응을 나타내었다. 이산화티탄의 백탁현상을 방지하기 위해서는 초미립자 이산화티탄을 사용해야 하고, 이로 인한 광독성으로 인해 높은 피부반응이 나타난 것이다. As shown in the above table, the general particle size titanium dioxide of Comparative Example 4 shows a very safe composition of 0.37, but when the ultrafine titanium dioxide of Comparative Example 1 is included, the average reactivity is 2.30, but a safe composition is slightly higher. Skin reactions were noted. To prevent turbidity of titanium dioxide, ultrafine titanium dioxide should be used, resulting in high skin reaction due to phototoxicity.
한편, 돌외잎추출물과 호장근추출물을 단독으로 함유한 비교예 2와 3의 경우에는 평균반응도는 낮게 나타났지만, 3주차에서는 피부자극정도를 나타내었다. 이것은 지속적인 항산화능력이 부족하여 나타난 결과이다. 돌외잎추출물, 호장근추출물을 복합하여 함유한 실시예 1의 자외선차단제의 경우에는 돌외잎추출물의 항산화력과 호장근추출물의 전자공여능의 상승효과로 인해 지속적으로 피부자극 반응도가 전혀 나타나지 않는 피부진정 자외선차단제를 완성할 수 있었다.On the other hand, in Comparative Examples 2 and 3 containing the extra-leaf extract and P. rootis extract alone, the average reactivity was low. This is a result of lack of sustained antioxidant capacity. In the case of the sunscreen of Example 1, which contains a combination of extra-leaf leaves and splendid muscle extracts, the skin calming effect does not occur at all due to the synergistic effect of the antioxidant power of the extra-leaf leaves extract and the electron donating ability of the extracts of the root extracts. The sunscreen could be completed.
Claims (1)
에탄올을 이용하여 돌외의 잎에서 추출한 돌외잎추출물을 0.1 내지 30.0 중량 %와 에탄올을 이용하여 호장근에서 추출한 호장근추출물을 0.1 내지 30.0 중량%를 포함하고 있으며,
전자공여능을 가진 호장근추출물이 돌외잎추출물의 항산화능력을 지속시키는 것을 특징으로 하는 돌외잎추출물과 호장근추출물을 함유한 피부 진정 자외선 차단 기능성 화장료 조성물.As used in sunscreen functional cosmetics containing ultrafine titanium dioxide having a particle size of 370 nm or less,
It contains 0.1 to 30.0% by weight of the stone extract extracted from the leaves of the dorsal leaves using ethanol and 0.1 to 30.0% by weight of the root extract extracted from the knotweed muscle using ethanol,
A skin calming sunscreen functional cosmetic composition containing a crypt extract and a pomace root extract, characterized in that the root extract of E. coli has an electron donating ability to maintain the antioxidant capacity of the foliar leaf extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110144316A KR101216410B1 (en) | 2011-12-28 | 2011-12-28 | Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract and resverol extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110144316A KR101216410B1 (en) | 2011-12-28 | 2011-12-28 | Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract and resverol extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101216410B1 true KR101216410B1 (en) | 2012-12-28 |
Family
ID=47908399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110144316A KR101216410B1 (en) | 2011-12-28 | 2011-12-28 | Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract and resverol extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101216410B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170118359A (en) * | 2016-04-15 | 2017-10-25 | 김세인 | Cosmetic composition containing gynostemma pentaphyllum leaf extract |
KR20190040593A (en) | 2017-10-11 | 2019-04-19 | 박명금 | Method of producing cream for anti-wrinkle solution |
KR20200013976A (en) | 2018-07-31 | 2020-02-10 | 박명금 | Method of producing eye cream for anti-wrinkle solution |
KR102364260B1 (en) | 2021-08-31 | 2022-02-17 | 주식회사 닥터에이 | Cosmetic composition for skin soothing containing complex extract including Gynostemma pentaphyllum, Saponaria officinalis L. and Lonicera Japonica Flower |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100667448B1 (en) | 2005-09-01 | 2007-01-10 | 주식회사 쵸이스코스메틱 | Cosmetic composition containing dodol extract |
-
2011
- 2011-12-28 KR KR1020110144316A patent/KR101216410B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100667448B1 (en) | 2005-09-01 | 2007-01-10 | 주식회사 쵸이스코스메틱 | Cosmetic composition containing dodol extract |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170118359A (en) * | 2016-04-15 | 2017-10-25 | 김세인 | Cosmetic composition containing gynostemma pentaphyllum leaf extract |
KR101881954B1 (en) * | 2016-04-15 | 2018-07-26 | 김세인 | Cosmetic composition containing gynostemma pentaphyllum leaf extract |
KR20190040593A (en) | 2017-10-11 | 2019-04-19 | 박명금 | Method of producing cream for anti-wrinkle solution |
KR20200013976A (en) | 2018-07-31 | 2020-02-10 | 박명금 | Method of producing eye cream for anti-wrinkle solution |
KR102364260B1 (en) | 2021-08-31 | 2022-02-17 | 주식회사 닥터에이 | Cosmetic composition for skin soothing containing complex extract including Gynostemma pentaphyllum, Saponaria officinalis L. and Lonicera Japonica Flower |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3636273B1 (en) | Novel formulations and uses for curcuma extracts | |
KR101327943B1 (en) | Composition based on mineral concentrates derived for precious stones | |
KR101851623B1 (en) | A cosmetic composition comprising spirulina extract for blue light interception | |
KR101073678B1 (en) | Shampoo composition using medical herbs and manufacturing method thereof | |
KR101928386B1 (en) | Cream type cosmetic composition having skin tone correcting, UV protecting, anti-wrinkle and whitening effect, and preparing method of the same | |
CN101933892B (en) | New application of kaempferol extractive and sunscreen cosmetic containing kaempferol extractive | |
CN102406577B (en) | Chinese medicine composite with sun-screening function and preparation method and application of extract thereof | |
KR101216410B1 (en) | Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract and resverol extract | |
KR102164246B1 (en) | Cosmetic Compositions for Anti-oxidation and Protecting Skin from UV Comprising Complex Extracts of Plants | |
CN106727150A (en) | A kind of sun-proof skin care cosmetic composition and its application | |
US20120107253A1 (en) | SUNSCREEN FORMULATIONS USING NATURAL OCEANIC CLAY (aka Marine Glacial Clay) | |
KR20130075962A (en) | Composition of sun screening functional cosmetics for skin soothing effect using gynostem extract | |
CN106176346B (en) | A kind of sunscreen composition, preparation method and sunscreen cosmetic | |
KR100668290B1 (en) | Baby swimming and / or rhubarb extract-containing cosmetic composition for improving atopic skin | |
KR100898308B1 (en) | Cosmetic composition having skin soothing effect | |
JP3636972B2 (en) | Whitening and cosmetics | |
KR101617730B1 (en) | Cosmetic composition with the extract of ginseng berry and grape seed and cosmetics using the same | |
ES2890232T3 (en) | Production of standardized extracts from the plant known as cuachalalate (Amphipterygium adstringens) and their uses as sun protection agents | |
KR102031289B1 (en) | A cosmetic composition comprising flankton extract for blue light interception | |
KR20060093164A (en) | Wrinkle Relieving Cosmetic Composition | |
US20250032569A1 (en) | Composition, in particular cosmetic formulation, comprising a verbascoside extract | |
KR20130024168A (en) | A cosmetic composition comprising tissue-cultured plants | |
Guo et al. | Sunscreens: What Might the Future Hold? | |
Singh et al. | Remediation of ultraviolet-rays induced skin damages by the phytochemical composition of herbal extracts | |
KR102030679B1 (en) | Sun screen composition comprising Panax ginseng polysaccharide and Green tea polysaccharide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20111228 |
|
PA0201 | Request for examination | ||
A302 | Request for accelerated examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20120102 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20111228 Patent event code: PA03021R01I Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120509 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20121115 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20121221 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20121221 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20151229 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20151229 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170621 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20170621 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171221 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20171221 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190515 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20190515 Start annual number: 7 End annual number: 7 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20201001 |